Abstract 400P
Background
Long non-coding RNAs (LncRNAs) play a critical part in tumor growth and metastasis, but only a small number of LncRNAs are functionally annotated.
Methods
The GEO database was used to analyze breast cancer-related transcriptome data and identify the differentially expressed LncRNA-LINC00294, and qRT-PCR was used to validate the expression of LINC00294 in 30 pairs of breast and para cancer tissues, as well as normal human breast epithelial cells MCF-10A and breast cancer cells MDA-MB-231, SK-BR-3, and MCF-7. The influence of LINC00294 overexpression/interference on the biological properties of breast cancer cells was validated using Western Blot, Transwell, scratch assay, flow cytometry, and CCK-8; the infection of LINC00294 overexpression on the growth of breast tumors in vivo was validated using an in situ tumorigenesis assay in nude mice; the effects of LINC00294 overexpression on the growth of breast tumors in vivo were inquired using Western Blot. The infection of LINC00294 in breast cancer cell biology was investigated by Western Blot, Transwell, scratch assay, and luciferase reporter to investigate the mechanism by which LINC00294 affects breast cancer development via ceRNA adsorption and thus regulates JUP expression.
Results
LINC00294 was significantly upregulated in breast cancer tissues. Furthermore, interference with LINC00294 significantly inhibited breast cancer cell multiplication, invasion, and migration, while overexpression of LINC00294 promoted breast cancer cell invasion proliferation, proliferation, and migration, as well as tumor growth. According to mechanistic studies, LINC00294 could regulate JUP expression and thus the Wnt/β-catenin signaling pathway by targeting miR-485-5p, thus affecting the development of breast cancer.
Conclusions
LINC00294 is highly expressed in breast cancer and may spaciously adsorb miR-485-5p through the ceRNA mechanism to regulate JUP expression, which in turn regulates the Wnt/β-catenin signaling pathway and affects the development of breast cancer. Our findings show that LINC00294 has an effect on breast cancer and identifies a new possible prognostic marker and therapeutic target for this disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
the 'Kuanren meritocrat'Backbone Talents Project of The Second Affiliated Hospital of Chongqing Medical University (no. KY2019G016), Wu Jiping Medical Foundation (no.320.6750.2021-10-86) and Natural Science Foundation of Chongqing, China(no.CSTB2022NSCQ-MSX0055).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
523P - A phase II study of intrapatient dose escalation of biweekly trifluridine/tipiracil plus bevacizumab for colorectal cancer (E-BiTS study)
Presenter: Munehiro Wakabayashi
Session: Poster session 15
524P - A phase II study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with metastatic colorectal cancer who failed two prior standard chemotherapies
Presenter: Ahreum Lim
Session: Poster session 15
525P - Final analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody
Presenter: Keiji Sugiyama
Session: Poster session 15
526P - Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: A FRESCO-2 subgroup analysis by age
Presenter: Maria Elena Elez Fernandez
Session: Poster session 15
527P - Effect of trifluridine/tipiracil (FTD/TPI) in combination with bevacizumab (bev) in patients treated in SUNLIGHT by clinical prognostic factors at baseline
Presenter: Josep Tabernero
Session: Poster session 15
529P - Evaluating metastatic disease sites as a prognostic marker in patients receiving sequential treatment with regorafenib and trifluridine/tipiracil for refractory colorectal cancer: Survival outcomes from the multicenter retrospective “ReTrITA” study
Presenter: Carlo Signorelli
Session: Poster session 15
530P - Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study
Presenter: Andreas Seeber
Session: Poster session 15
531P - Prognostic value of liver metastases, KRAS mutations and race in colorectal cancer patients: A pooled analysis of third-line placebo-controlled trials from the ARCAD database
Presenter: Thierry André
Session: Poster session 15
532P - G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study
Presenter: Jean-Baptiste Bachet
Session: Poster session 15